AS2863619

Overview

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2 , MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis ( apoptosis ). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > STAT | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-126675A
• CAS No.: 2241300-51-4
• Molecular Formula: C16H14Cl2N8O
• Molecular Weight: 405.24
• Purity: 98.02%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.62 mg/mL (6.47 mM); Clear solution
• Availability: In-stock

Source

Original product source